Cancer Genetics Reports 45 Percent Increase in Q1 Revenues, Maps out Growth Strategy | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics today said that its first-quarter revenues jumped 45 percent year over year, as it reported financial results for the first time as a publicly traded company.

Revenues for the three months ended March 31 were $1.2 million, compared to $834,752 during the first quarter in 2012. Clinical test volume increased to 1,911 tests in the quarter, up 19 percent from 1,610 in the year-ago period, while average revenue per test rose 23 percent to $615 from $502 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.